In this episode, I discuss a medication known as adalimumab (Humira).
Everybody welcome back to another episode of drug talk as always i’m your host garrett campbell today we’re gonna be talking about a medication known as adalimumab it’s brand name is humera now before i talk about the medication itself just keep in mind that this channel is for information purposes only and not to be used as a source for recommendations for your
Personal healthcare so adalimumab binds specifically to tumor necrosis factor-alpha and it blocks its interaction with p 55 and p 75 cell surface receptors these receptors would be specific to tnf adalimumab does not bind to or inactivate lympho toxin which would be tnf beta adalimumab also modulates biological responses that are induced or regulated by tumor
Necrosis factor this would include changes in levels of adhesion molecules that are responsible for leukocyte migration finally adalimumab decreases c-reactive protein a retro site sedimentation rate and matrix metalloproteinases there are many different situations when we see this medication used so i’ll go over some of the indications here with you now can be
Used to treat ankylosing spondylitis we see it used in moderate to severe crohn’s disease should be reserved for patients who have had inadequate responses from conventional therapies it can be used to treat hidradenitis suppurativa in moderate or severe cases juvenile idiopathic arthritis can be treated with humera moderate or severe chronic plaque psoriasis
Can also be treated with adalimumab psoriatic arthritis as well as rheumatoid arthritis may also be treated with this medication in moderate or severe cases active moderate or severe ulcerative colitis can be treated with adalimumab and finally uveitis can be treated with this medication now before somebody was prescribed adalimumab there are some warnings and
Precautions that they should be made aware of new onset as well as worsening of heart failure has been reported by patients who use adalimumab the lemieux map cannot be used with a bad acept or anakinra as well as live vaccines melanoma as well as non-melanoma skin cancers have been reported be mythological abnormalities have been reported and they may result in
The discontinuation of therapy serious and sometimes fatal infections have been reported with the use of adalimumab patients would be an increased risk of experiencing these infections if they are immunocompromised or if they’re above the age of 65 pediatric patients should be brought up to speed on all of their immunizations before they start using adalimumab
Auto antibody formation may occur and this may turn into something that resembles lupus like syndrome if somebody has an active infection this would include a localized infection they should stop adalimumab and also if somebody is not yet using the medication they should wait until the infection clears before starting it must be used cautiously in patients with
A history of opportunistic infections this would also count for patients who have underlying conditions which would predispose them to an infection anaphylaxis as well as angioedema have both been reported with adalimumab malignancies have been reported in adults an interesting note here is that health care professionals have to use caution when their immunizing
Infants who have been exposed to adalimumab in utero and the last thing to note here is just that for patients who may have a latex allergy the grey cover that goes over the 27-gauge needle does contain latex now when somebody is made aware of the precautions and warnings and they start using adalimumab they can expect to take it in different doses depending on
The reason that they’ve been prescribed it in ankylosing spondylitis the typical dose would be given subcutaneously at 40 milligrams once every other week people are using adalimumab to treat crohn’s disease they would start off with a dose of 160 milligrams taking subcutaneously some patients do choose to take this day one dose and split it up over two days
And then two weeks later on day 15 they would use 80 milligrams subcutaneously and then 40 milligrams subcutaneously would be given every other week starting on day 29 and treating plaque psoriasis the typical starting dose here would be 80 milligrams subcutaneously then they will be using 40 milligrams subcutaneously every other week but they would start this
Seven days after their first dose in rheumatoid arthritis the typical dose would be 40 milligrams subcutaneously every other week but these patients do have the option to increase their dosing to take 40 milligrams every week only patients that are not also using methotrexate can increase the frequency to weekly now as with all medications there are some adverse
Reactions or side-effects that people may experience while using adalimumab so i’ll go over some of those here for you now six to nineteen percent of patients experience pain at the injection site junction site reactions happen 5 to 20 percent of the time rash happens 12 percent of the time about 12 percent of patients experience a headache and 11 percent develop
Sinusitis 17 percent experience upper respiratory tract infections i’m gonna list off a few cardiovascular side-effects now there are possibilities with this medication each of these side-effects happens less than 5% of the time atrial fibrillation cardiac arrest chest pain congestive heart failure myocardial infarction syncope pericarditis and finally pericardial
Effusion you know i know dermatological side-effects patients may experience steven johnson syndrome in their gastrointestinal tract they may experience a hemorrhage agranulocytosis as well as leukopenia are both possible but they are rare bone necrosis happens less than 5% of the time also less than 5% of the time patients may experience a subdural hematoma and
Finally difficulty breathing and bronchospasm may also happen to patients the development of an infectious disease would be considered a side-effect however because it’s so common with this medication it’s better just to tell all patients to watch out for any signs of infection and to report them to their physician as soon as they do notice them it’s all we’re
Gonna talk about today with adalimumab or humera as always i’m thankful that you took the time to come by and watch one of my videos if you found the information valuable and you’d like to help me grow this channel you can like the videos share the videos or most importantly subscribe to the youtube channel there’s also some links in the description you can check
Out as well is that for today take care
Transcribed from video
ADALIMUMAB (HUMIRA) – PHARMACIST REVIEW – #64 By Drug Talk
